9 e& Q& H. L+ y% q9 s. E9 G% R k
麻烦大叔告诉我第三个的理由是什么?
/ x, |& `! v0 |' v临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:# I" _% `5 l6 x, B
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.2 r" b, \" @/ [! f http://www.ncbi.nlm.nih.gov/pubmed/22968184( T. A( r1 K' V- a0 \. q: A